Oct 11, 2022 in Drug Delivery, Press Releases
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”).
Over the past 90 days, the Company has been focused on the optimization of its Rotigotine TDS formulation for the treatment of Parkinson’s disease, with multiple novel but related formulas under development. After several rounds of skin permeation studies using mouse and human cadaver skin samples to compare Rotigotine absorption between XPhyto’s formulas and the name brand product, XPhyto is pleased to announce that its Rotigotine TDS formula is complete.
Upon the recent formula completion, the Company carried out what it anticipates to be the final comparative human skin cadaver study. This study is now complete and analytical results are expected to be finalized and announced within the coming days.
Rotigotine is a non-ergoline dopamine agonist approved for the treatment of Parkinson’s disease and restless legs syndrome (RLS) in Europe and the United States. The active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability and provide a slow and steady supply of the drug over the course of 24 hours. The therapeutic market for Parkinson’s Disease is over 10 million people with PD worldwide and growing. The top selling name brand product launched by the originator in 2007 independently sold over $375 million of its Rotigotine TDS patches in 2021. According to Wissen Market Research, total global sales for Rotigotine patches were approximately US$518 million in 2021 with the market expected to surpass US$766 million by 2030.
XPhyto’s Rotigotine transdermal product is a single product based on its 100% owned platform technology which represents a scalable opportunity for additional TDS drug development and manufacturing programs. According to Research and Markets, the global transdermal skin patch market had a value of nearly US$6.5 billion in 2020 while Kuick Research, Pharmaceutical and Healthcare, estimate the market will reach approximately US$20 billion by 2028.
Vektor, a wholly owned XPhyto subsidiary, is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sub-lingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global drug delivery market was valued at US$1,476 billion in 2021 and is expected to grow to US$2,047 billion by 2030.